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TRACKING THE GROWTH RATE OF BRAIN METASTASES
BENJAMIN CICCARELLI, GREGORY KUBICEK1, MD, ALAN TURTZ2, MD,
PIYA SARAIYA3, MD, HOWARD WARREN GOLDMAN2, MD
1Department

of Radiation Oncology, 2Department of Neurological
Surgery, 3Department of Diagnostic Radiology

Introduction

Methods
All Masses, Size by Greatest Dimension (cm)
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• Brain metastases are a common complication of cancer and are thought to
occur in up to one-fourth of all cancer patients
• While abundant research has been done on the different treatment
modalities for brain metastases, literature is relatively sparse on their
growth rate

• This qualitative study includes 21 patients treated with Gamma Knife
therapy at MD Anderson of Cooper University Hospital
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• All patients had never received stereotactic radiosurgery (SRS) in the
past or during the timeframe between imaging to treatment
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• The time delay between imaging and delivery of treatment may result in
clinically significant tumor growth that could alter treatment planning
• In Cyberknife therapy, treatment planning may be based on imaging
obtained >1 week before treatment administration, in contrast to Gamma
Knife therapy, where a pretreatment MRI is always obtained within hours
of treatment
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(Avg Δt: 20.39 days)

• No patients were receiving chemotherapy during this timeframe

Date 2

• All patients had 2 MRI imaging sets at separate dates, a diagnostic
MRI and a pretreatment MRI
• Imaging sets were retrospectively reviewed to measure volume, size of
greatest dimension, and type of lesions using Pinnacle software

All Masses, Size by Lesion Volume (mL)

• There are no current recommendations for imaging to treatment delay as
of this time
• Understanding of growth rate in brain metastases can increase the
confidence of radiation oncologists on the effects of delay in treatment
and help determine the value of radiation therapy for poor performance
patients
• The goal of our study is to determine a general growth rate for brain
metastases to address the uncertainties of delay of treatment and
determine the value of radiation therapy in poor performance patients
• We hypothesize that the masses will not outgrow a 2-mm expansion of
margins from initial diagnostic MRI to pre-treatment (Gamma-knife)
MRI

• These 21 patients had various amounts of brain metastases, totaling
38 metastases
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Results
• Our collected data is over a mean time span of 20.39 ± 16.54 days
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• The mean volume of brain metastases grew from 1.31 ± 1.92 mL to
1.92 ± 2.66 mL The average growth rate of all masses by volume was
0.03mL/day ± 0.06
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Mass Characteristics

(Avg Δt: 20.39 days)
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• During this same time frame, the mean size of greatest dimension
grew from 1.23 ± 0.73 cm to 1.45 ± 0.71 cm. The average growth rate
of all masses by size of greatest dimension was 0.12mm/day ± 0.23

Brain Metastases Covered by
2mm Expansion

• 20 of the 38 masses would be covered by a 2mm expansion of margins
surrounding the brain metastases

Conclusion
• Our results show 52.63% of masses were covered by a 2mm expansion
of margins at an average of 20.39 days. This emphasizes the
importance of minimizing delays in treatment from diagnosis
• A larger sample size of brain metastases would give us growth rates
more specific to the source of cancer and provide greater clinical
utility
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• More research should be done on this subject to help predict growth
rates of certain cancers and determine the value of radiation therapy
in poor performance patients
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